Dr. Agarwal’s Health Care Limited (AGARWALEYE) breaks out, gaining +5% to ₹518.3 on the NSE on 05 Aug 2026. The stock cleared its 6-month resistance trendline, marking a shift from a breakdown to a breakout. This move is company-specific, as the healthcare sector, particularly medical instruments and supplies, has shown mixed momentum. AGARWALEYE’s breakout indicates renewed investor confidence, possibly driven by recent corporate announcements and the company’s expansion plans.

Technical setup — trendlines & DMA

The current trendline structure shows a 6-month support floor at ₹497.18, which is 4.07% below today’s price. Resistance was at ₹500.47, which the stock has now broken by 3.44%. The 50-DMA at ₹473.5 and the 200-DMA at ₹471.5 are both below the current price, indicating a bullish trend. The stock is in the upper third of its 52-week range, suggesting that while there is still room for growth, a significant portion of the potential move may already be priced in.

Fundamentals & business context

With a PE of 118.6 and profit margins at 6.4%, AGARWALEYE’s valuation appears stretched relative to its current earnings, especially given its revenue CAGR of 27.0%. The market seems to be pricing in future growth and expansion, rather than current profitability. Institutional ownership stands at 19.2%, indicating that smart money has a moderate level of confidence in the company’s prospects. There is no specific NSE catalyst today, but the stock’s move likely reflects broader investor sentiment and the company’s growth narrative.

Algorithmic scorecard

The overall scorecard reflects a technically strong but fundamentally weak position. The strongest signals include the bullish trend, with the 50-DMA above the 200-DMA, and the consistent revenue growth every year, indicating exceptional business stability. These factors suggest that the company has a solid growth trajectory and market position. However, the weakest signals are the low profit margin of 6.4% and the overvalued PEG of 9.64, which indicate thin profits and an expensive valuation relative to growth. These risks could pose challenges if the company faces increased costs or if growth expectations are not met.

Company outlook

Management expects EBITDA margins to remain stable despite continued investment in greenfield expansion. They anticipate a sizable improvement in both revenue and profitability from the new CMS facility once operational. A significant increase in volumes and realization is expected once the new facility in Chennai is commissioned by October 1, 2026. The company plans to commission 60 new facilities across the year, with 30 each in the first and second half. These initiatives underscore the company’s aggressive expansion strategy and commitment to growth.

Get all details on AGARWALEYE — P&L, peers, shareholding and more on TradeAlone.